Immunocore says TEBE-AM trial hit target enrollment
Immunocore announced achievement of target enrollment in the registrational TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma.
Story updates
11:24:31 AM UTC
SquawkNews
Immunocore announced achievement of target enrollment (540 patients) in the Phase 3 TEBE-AM trial and expects topline overall survival data as early as end of 2026.Key Highlights:Original SEC Filing: Immunocore Holdings plc [ IMCR ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.